Anticoagulant therapy: Basic principles, classic approaches and recent developments

Blood Coagulation and Fibrinolysis

Volumn 23, Issue 6, 2012, Pages 482-493

  Sinauridze, Elena I ^a,b   Panteleev, Mikhail A ^a,b,c,d   Ataullakhanov, Fazoil I ^a,b,c,d,e  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b CENTER FOR THEORETICAL PROBLEMS OF PHYSICOCHEMICAL PHARMACOLOGY   (Russian Federation)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

^d HemaCore LLC   (Russian Federation)

^e Federal Research and Clinical Center of Pediatric Hematology   (Russian Federation)

Author keywords

antiplatelet agents; antithrombotic therapy; blood coagulation; dabigatran; direct thrombin inhibitors; heparin; thrombosis; vitamin K antagonists; warfarin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; EDOXABAN; FIBRIN; FIBRINOGEN RECEPTOR; FONDAPARINUX; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PROTEINASE ACTIVATED RECEPTOR 1; PROTHROMBIN; PROTHROMBIN A; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; THROMBIN; THROMBIN INHIBITOR; THROMBOMODULIN; TIROFIBAN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; WARFARIN;

ABDOMINAL BLEEDING; ANTICOAGULANT THERAPY; BLEEDING; DEEP VEIN THROMBOSIS; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; FIBRIN CLOT; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; LUNG EMBOLISM; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; PLATELET AGGREGATION INHIBITORS; THROMBIN; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS; VITAMIN K; WARFARIN;

EID: 84865446716     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328355c9cb     Document Type: Review

References (98)

1. Choi SH, Smith SA, Matsushita T, Kojima T. Historical perspective and future direction of coagulation research. J Thromb Haemost 2011; 9 (Suppl 1): 352-363.
2. Muller F, Gailani Du , Renne T. Factor XI and XII as antithrombotic targets. Curr Opin Hematol 2011; 18:349-355.
3. Hirsh J. Fondaparinux. Hamilton, Ontario, Canada: BC Decker Inc.; 2007. pp. 58.
4. Hirsh J. Heparin. N Engl J Med 1991; 324:1565-1574.
5. Hirsh J, Warkentin TE, Raschke R, Granger C, Olman EM, Dalen JE. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy and safety. Chest 1998; 114:489S-510S. (Pubitemid 28535777)
6. Lindahl U, Hook M. Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem 1978; 47:385-417.
7. Shafer JA. Cardiovascular chemotherapy: anticoagulants. Curr Opin Chem Biol 1998; 2:458-465. (Pubitemid 128645698)
8. De Prost D. Heparin fractions and analogues: a new therapeutic possibility for thrombosis. Trends Pharm Sci 1986; 7:496-500.
9. Boneu B. Low molecular weight heparins: are they superior to unfractionated heparins to prevent and to treat deep vein thrombosis? Thromb Res 2000; 100:V113-V120.
10. Cohen M. The role of low-molecular-weight heparins in arterial diseases: optimizing antithrombotic therapy. Thromb Res 2000; 100:V131-V139.
11. Bourin M-C, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289:313-330. (Pubitemid 23042035)
12. Jesty J. The kinetics of inhibition of (-thrombin in human plasma. J Biol Chem 1986; 261:10313-10318. (Pubitemid 17221969)
13. Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261:15467-15473. (Pubitemid 17208768)
14. Olson ST, Shore JD. Demonstration of a two-step reaction mechanism for inhibition of (-thrombin by antithrombin III and identification of the step affected by heparin. J Biol Chem 1982; 257:14891-14895. (Pubitemid 13159581)
15. Chaoy J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structureactivity relationship in hepar: a synthetic pentasaccharide with high affinity for antithrombin III eliciting high antifactor Xa activity. Biochem Biophys Res Commun 1983; 116:492-499. (Pubitemid 14242772)
16. Rosenberg R. Biochemistry and pharmacology of low molecular weight heparin. Semin Hematol 1997; 34 (Suppl 4):2-8. (Pubitemid 27518238)
17. Theroux P, Quimet H, McCans J, Latour JG, Joly P, Levy G, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-1111.
18. Wallentin L, for the RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-830. (Pubitemid 20311324)
19. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, et al., the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary points from the ATACS trial. Circulation 1994; 89:81-88. (Pubitemid 24026475)
20. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduced the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276:811-815. (Pubitemid 26301581)
21. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327:141-145.
22. Hirsh J. Low-molecular-weight heparin: a review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation 1998; 98:1575-1582. (Pubitemid 28481675)
23. Young E, Podor J, Vemer T, Hirsh J. Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arterioscler Thromb Vasc Biol 1997; 17:1568-1574. (Pubitemid 27387779)
24. Melandri G, Semprini F, Cervi V, Candiotti N, Branzi A, Palazzini E, Magnani B. Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects. Am J Cardiol 1993; 72:450-454. (Pubitemid 23238431)
25. Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Coron Artery Dis 1997; 8:105-111. (Pubitemid 27248437)
26. Briant L, Caranobe C, Saivin S, Sie P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY216: pharmacokinetics and bioavalilabilities of the antifactor Xa and IIa: effects of intravenous and subcutaneous injection in rabbits. Thromb Res 1989; 61:348-353. (Pubitemid 19168134)
27. Olson ST, Bjork I. Regulation of thrombin by antithrombin and heparin cofactor II. In: Berliner LJ, editor. Thrombin: structure and function. New York, New York: Plenum Press; 1992. pp. 159-217.
28. Rosenberg RD. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis, thrombosis: basic principles, clinical, practice. 2nd ed. Philadelphia: JB Lippincott; 1987. pp. 1373-1392.
29. Greinacher A. Heparin-induced thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl 1):9-12.
30. Griffith GC, Nichols G, Asher JD, Flanagan B. Heparin osteoporosis. JAMA 1965; 193:85-88.
31. Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P. Pharmacokinetic studies of standard UFH, and low molecular weight heparins in the rabbit. Semin Thromb Hemost 1988; 14:18-27. (Pubitemid 18096093)
32. Caranobe C, Barret A, Gabaig AM, Dupouy D, Sie P, Boneu B. Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and low molecular weight heparin (CY216) in normal and nephrectomized rabbits. Thromb Res 1985; 40:129-133. (Pubitemid 16204034)
33. Palm M, Mattsson CH. Pharmacokinetics of heparin and low molecular weight heparin (fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58:932-935. (Pubitemid 18020466)
34. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677-681. (Pubitemid 26079800)
35. Koopman MMW, Prandoni P, Piovella F, Oskelford PA, Brandjes DP, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682-687.
36. Tadros R, Shakib S. Warfarin: indications, risks and drug interactions. Aust Fam Physician 2010; 39:476-479.
37. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9-3. Pharmacogenetics 1997; 7:361-367. (Pubitemid 27427545)
38. Bauer KA. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J Thromb Haemost 2011; 9 (Suppl 1):12-19.
39. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993; 329:1370-1376. (Pubitemid 23317346)
40. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271:1780-1785. (Pubitemid 24166618)
41. Hull RD, Raskob GE, Pineo GF, Feldstein W, Rosenbloom D, Gafni A, et al. Subcutaneous low-molecular-weight heparin vs warfarin for prophylaxis of deep vein thrombosis after hip or knee implantation. Arch Intern Med 1997; 157:298-303. (Pubitemid 27066398)
42. Eichinger S, Pabinger I, Stumpflen A, Hirschl M, Bialonczyk C, Schneider B, et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77:624-628. (Pubitemid 27182953)
43. Schulman S,Granqvist S, HolmstromM, Carlsson A, Lindmarker P, Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997; 336:393-398. (Pubitemid 27081901)
44. Philippides GJ, Loscalzo J. Potential advantages of direct-acting thrombin inhibitors. Coron Artery Dis 1996; 7:497-507. (Pubitemid 26365625)
45. Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90:1624-1630. (Pubitemid 24320906)
46. Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 1994; 90:1638-1642.
47. Tidwell RR, Webster WP, Shaver SR, Geratz JD. Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitors versus thrombin inhibitors. Thromb Res 1980; 19:339-349. (Pubitemid 10029564)
48. Pauls HW, Ewing WR. The design of competitive, small-molecule inhibitors of coagulation factor Xa. Curr Top Med Chem 2001; 1:83-100.
49. Bauer KA. New anticoagulants. Hematology Am Soc Hematol Educ Program 2006; 2006:450-456.
50. Claeson G. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Blood Coagul Fibrinolysis 1994; 5:411-436. (Pubitemid 24173457)
51. Scarborough RM. Coagulation factor Xa: the prothrombinase complex as an emerging therapeutic target for small molecule inhibitors. J Enzyme Inhib 1998; 14:15-25. (Pubitemid 29017184)
52. Dudley DA, Bunker AM, Chi L, Cody WL, Holland DR, Ignasiak DP, et al. Rational design, synthesis and biological activity of benzoxazinones as novel factor Xa inhibitors. J Med Chem 2000; 43:4063-4070.
53. Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25:4622-4628. (Pubitemid 16010197)
54. Dodt J, Kohler S, Baici A. Interaction of site specific hirudin variants with alpha-thrombin. FEBS Lett 1988; 229:87-90. (Pubitemid 18058753)
55. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW 2nd. Science 1990; 249:277-280.
56. Rydel TJ, Tulinsky A, Bode W, Huber R. Refined structure of the hirudinthrombin complex. J Mol Biol 1991; 221:583-601.
57. Menear K. Direct thrombin inhibitors: current status and future prospects. Exp Opin Invest Drugs 1999; 8:1373-1384. (Pubitemid 29417621)
58. Lubenow N, Creinacher A. Heparin-induced thrombocytopenia: recommendation for optimal use of recombinant hirudin. Biodrugs 2000; 14:109-125.
59. Steinmetzer T, Hauptmann J, Sturzebecher J. Advances in the development of thrombin inhibitors. Exp Opin Invest Drugs 2001; 10:845-864. (Pubitemid 32421981)
60. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor agratroban on fibrin- or clot-incorporated thromb: comparison with heparin and recombinant hirudin. Thromb Haemost 1994; 72:381-386. (Pubitemid 24280776)
61. Refludan Product Monograph. 2006. Wolters Kluwer Health Pharma Solutions (Europe) Limited, pp. 44. http://www.bayer.ca/files/REFLUDANPM-ENG-29MAY2007- 113596.pdf (accessed 1 June 2012)
62. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW II. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990; 29:7095-7101. (Pubitemid 20241158)
63. Callas DD, Hoppensteadt D, Fareed J. Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog and hirudin. Semin Thromb Hemost 1995; 21:177-183.
64. Scatena R. Bivalirudin: a new generation antithrombotic drugs. Exp Opin Invest Drugs 2000; 9:1119-1127. (Pubitemid 30255571)
65. Nisio MDI, Middeldorp S, Buller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028-1040. (Pubitemid 41262337)
66. Straub A, Roehrig S, Hillisch A. Oral, direct thrombin and factor Xa inhibitors: the replacement for warfarin, leeches, and pig intestines? Angew Chem Int Ed 2011; 50:4574-4590.
67. Bauer KA. New anticoagulants: anti IIa vs anti Xa - is one better? J Thromb Thrombolysis 2006; 21:67-72. (Pubitemid 43231131)
68. Schwarz RP. The preclinical and clinical pharmacology of Novastan (argatroban). In: Pifarre R, editor. New anticoagulants for the cardiovascular patient. Philadelphia, Pennsylvania: Hanley and Belfus Inc.; 1997. pp. 231-249.
69. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, et al. Potent inhibition of thrombin by the newly synthesized arginine derivative no.805. The importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun 1981; 101:440-446.
70. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007; 64:292-303. (Pubitemid 47283865)
71. Turpie AGG, Eriksson BI, Bauer KA, Lassen MR. Advances in therapeutics and diagnostics: fondaparinux. JAmAcad Orthop Surg 2004; 12:371-375.
72. Ansell J. New anticoagulants and their potential impact on the treatment of thromboembolic disease. Curr Hematol Rep 2004; 3:357-362.
73. Turpie AGG, Bauer KA, Eriksson BI, Lassen MR, for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. Arch Intern Med 2002; 162:1833-1840.
74. Zalpour A, Kroll MH, Afshar-Kharghan V, Yusuf SW, Escalante C. Role of factor Xa inhibitors in cancer-associated thrombosis: any new data? Adv Hematol 2011; 2011:196135.
75. Morell J, Sullivan B, Khalabuda M, McBride BF. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban. J Clin Pharmacol 2010; 50:986-1000.
76. Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011; 105:444-453.
77. Matsuo T. Argatroban. Antithrombotic therapy in clinical practice. Kobe, Japan: Kobe Research Projects on Thrombosis and Haemostasis; 2007. pp. 1.
78. Babuin L, Pengo V. Argatroban in the management of heparin-induced thrombocytopenia. Vasc Health Risk Manag 2010; 6:813-819.
79. Young G. New anticoagulants in children. Hematology Am Soc Hematol Educ Program 2008; 2008:245-250.
80. Akimoto K, Klinkhardt U, Zeiher A, Niethammer M, Harder S. Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokineticpharmacodynamic relationship of coagulation parameters. J Clin Pharmacol 2011; 51:805-818.
81. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30:1885-1889.
82. Ansell J. Warfarin versus new agents: interpreting the data. Hematology Am Soc Hematol Educ Program 2010; 2010:221-228.
83. van Ryn J, Stangier J, Haertter S, Liesenfeld K, Hienen W, Feuring M, Clemens A. Dabigatran etexilate: a novel reversible, oral direct thrombin inhibitor - interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116-1127.
84. Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood 2010; 115:15-20.
85. Herbert JM, He rault JP, Bernat A, van Amsterdam RG, Lormeau JC, Petitou M, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197-4205. (Pubitemid 28261983)
86. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al., Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 2004; 140:867-873.
87. Buller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al., Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349:1695-1702. (Pubitemid 37315006)
88. Buller HR. On behalf of the Van Gogh Investigators. Once weekly subcutaneous idraparinux versus placebo in the extended treatment of deep-vein thrombosis or pulmonary embolism. Blood 2006; 108:abstract 571.
89. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomized double-blind trial. Lancet 2010; 375:807-815.
90. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363:2487-2498.
91. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol 2007; 27:2507-2513. (Pubitemid 350158899)
92. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139:1143-1156.
93. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118:6963-6970
94. Butenas S, Mann KG. Blood coagulation. Biochemistry 2002; 67:3-12.
95. Ataullakhanov FI, Vorobiev AI, Butilin AA, Sinauridze EI,Ovanesov MV. Why the deficiencies of the factors of the intrinsic coagulation pathway result to hemophilia [in Russian, abstract in English]. Problems Haematol Blood Transfusion (Moscow) 2003; 1:7-13.
96. Ovanesov MV, Krasotkina JV, Ul'yanova LI, Abushinova KV, Plyushch OP, Domogatskii SP, et al. Hemophilia A and B are associated with abnormal spatial dynamics of clot growth. Biochim Biophys Acta 2002; 1572:45-57. (Pubitemid 35223055)
97. Negrier C, Dargaud Y, Bordet JC. Basic aspects of bypassing agents. Haemophilia 2006; 12 (Suppl 6):48-52.
98. Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, et al. Factor XIIa inhibitor recombinant human albumin infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 2010; 121:1510-1517.